197 related articles for article (PubMed ID: 20425327)
1. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
5. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
Ravoet C; Mineur P; Robin V; Debusscher L; Bosly A; André M; El Housni H; Soree A; Bron D; Martiat P
Ann Hematol; 2008 Nov; 87(11):881-5. PubMed ID: 18641985
[TBL] [Abstract][Full Text] [Related]
6. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Caponigro F
Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Cortes J
Clin Lymphoma; 2003 Aug; 4 Suppl 1():S30-5. PubMed ID: 14556673
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
Cortes JE; Kurzrock R; Kantarjian HM
Semin Hematol; 2002 Jul; 39(3 Suppl 2):26-30. PubMed ID: 12214290
[TBL] [Abstract][Full Text] [Related]
9. Farnesyl transferase inhibitors in the treatment of breast cancer.
Kelland LR
Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
[TBL] [Abstract][Full Text] [Related]
11. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Feldman EJ; Cortes J; DeAngelo DJ; Holyoake T; Simonsson B; O'Brien SG; Reiffers J; Turner AR; Roboz GJ; Lipton JH; Maloisel F; Colombat P; Martinelli G; Nielsen JL; Petersdorf S; Guilhot F; Barker J; Kirschmeier P; Frank E; Statkevich P; Zhu Y; Loechner S; List A
Leukemia; 2008 Sep; 22(9):1707-11. PubMed ID: 18548095
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235
[TBL] [Abstract][Full Text] [Related]
13. In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors.
Kotsianidis I; Bazdiara I; Anastasiades A; Spanoudakis E; Pantelidou D; Margaritis D; Bourikas G; De Coster R; De Porre P; Tsatalas C
Acta Haematol; 2008; 120(1):51-6. PubMed ID: 18824842
[TBL] [Abstract][Full Text] [Related]
14. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
Epling-Burnette PK; Loughran TP
Expert Opin Investig Drugs; 2010 May; 19(5):689-98. PubMed ID: 20402600
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity of tipifarnib in hematologic malignancies.
Jabbour E; Kantarjian H; Cortes J
Expert Opin Investig Drugs; 2007 Mar; 16(3):381-92. PubMed ID: 17302532
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase inhibitors: where are we now?
Tsimberidou AM; Chandhasin C; Kurzrock R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1569-80. PubMed ID: 21083522
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
[TBL] [Abstract][Full Text] [Related]
19. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Karp JE; Lancet JE
Future Oncol; 2005 Dec; 1(6):719-31. PubMed ID: 16556050
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Kurzrock R; Kantarjian HM; Blascovich MA; Bucher C; Verstovsek S; Wright JJ; Pilat SR; Cortes JE; Estey EH; Giles FJ; Beran M; Sebti SM
Clin Cancer Res; 2008 Jan; 14(2):509-14. PubMed ID: 18223226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]